<DOC>
	<DOCNO>NCT01123564</DOCNO>
	<brief_summary>This study aim assess Lucentis injection apply eye superior conventional treatment concern prevention visual loss patient clinically significant macular edema secondary retinal vein occlusion</brief_summary>
	<brief_title>Efficacy Safety Lucentis Clinically Significant Macular Edema Secondary Central Retinal Vein Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Macular edema persist 3 month period despite conventional medication . Central retinal vein occlusion confirm slitlamp biomicroscopy fluorescein angiography ( FLAG ) . Patients randomize ranibizumabtreated group receive macular laser treatment . Macular edema define OCT : thickness central foveal area calculate macular map analysis 280 μm and/or retinal thickness 330 μm region macula calculate retinal thickness analysis . Baseline visual acuity le 64 ETDRS letter ( 0.4 decimal equivalent ) . Diabetes mellitus Additional vitreoretinal disease History par plana vitrectomy Previous macular grid laser treatment Intravitreal triamcinolone acetonid treatment Complicated cataract surgery Advanced glaucomatous damage optic nerve head Cataract ( except mild , define grade 1 nuclear sclerosis and/or grade 1 posterior subcapsular cataract ) Agerelated macular degeneration Pregnancy lactation Women childbearing potential use double safe contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>macular edema secondary retinal vein occlusion</keyword>
</DOC>